ABSTRACT
This chapter reviews the advances that have been made with a variety of systemic hormonal therapies, all of which have enhanced the survival of women with ER-positive breast cancer. In addition, this chapter discusses the current guidance that is available for the optimal use of systemic hormonal therapies, and looks to the future as we start to classify ER-positive breast cancer into different intrinsic subtypes for which novel hormonal strategies involving combination with targeted biological agents may soon be evaluated in the adjuvant setting.
